Nouscom: developing the next generation immunotherapeutics for selective tumor killing

Nouscom is a Basel-based clinical-stage oncology company launched in 2015 and backed by an impressive roster of international life science investors: 5AM, Abingworth, Life Sciences Partners (LSP) and Versant Ventures. Nouscom raised 54 million Euro of venture capital to date in two financing rounds.

The company develops next-generation cancer vaccines based on its proprietary Exovax platform, which harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Its lead program NOUS-209 is being developed as a therapeutic vaccine for cancers characterized by Microsatellite Instability.

NOUS-209 is potentially the first neoantigen off-the-shelf cancer vaccine to be tested in the clinic. In 2017, Nouscom announced very compelling preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics’ NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials, demonstrating complete response in 100% of treated animals. Learn more about their rapidly expanding portfolio, their plans for the future and their approach to developing personalized cancer vaccines.